Suppr超能文献

[一名血液透析患者因再次感染严重急性呼吸综合征冠状病毒2导致新型冠状病毒肺炎复发:去而复返]

[COVID-19 recurrence due to reinfection with SARS-CoV-2 in a hemodialysis patient: there and back again].

作者信息

Vigotti Federica N, Bianco Simona, Alfieri Victor, Bilucaglia Donatella, Motta Daria, Pignataro Angelo, Timbaldi Marco, Torta Elisa, Cesano Giulio

机构信息

Nefrologia e Dialisi, Ospedale Martini, ASL Città di Torino, Torino, Italy.

出版信息

G Ital Nefrol. 2022 Apr 21;39(2):2022-vol2.

Abstract

The COVID-19 pandemic has caused millions of infections and deaths so far. After recovery, the possibility of reinfection has been reported. Patients on hemodialysis are at high risk of contracting SARS-CoV-2 and developing serious complications. Furthermore, they are a relatively hypo-anergic population, in which the development and duration of the immune and antibody response is still partially unknown. This may play a role in the possible susceptibility to reinfection. To date, only 3 cases of SARS-CoV-2 reinfection from strains prior to the Omicron variant in patients on chronic hemodialysis have been reported in literature. In all of them, the first infection was detected by screening in the absence of symptoms, potentially indicating a poor immune response, and there are no data about the antibody titre developed. We report a case of recurrence of COVID-19 in 2020 - first infection likely from Wuhan strain; reinfection likely from English variant (Alpha) after 7 months - in a hemodialysis patient with clinical symptoms and pulmonary ultrasound abnormalities. Swabs were negative in the interval between episodes (therefore excluding any persistence of positivity) and the lack of antibody protection after the first infection was documented by the serological test. The role of the potential lack - or rapid loss - of immune protection following exposure to SARS-CoV-2 in hemodialysis patients needs to be better defined, also in consideration of the anti-COVID vaccination campaign and the arrival of the Omicron variant, which appears to elude the immunity induced by vaccines and by previous variants. For this purpose, prospective multicenter studies are in progress in several European countries. This case also highlights the need for a careful screening with nasopharyngeal swabs in dialysis rooms, even after patients overcome infection and/or are vaccinated.

摘要

截至目前,新冠疫情已导致数百万人感染和死亡。康复后,再次感染的可能性已被报道。接受血液透析的患者感染新冠病毒并出现严重并发症的风险很高。此外,他们是相对免疫功能低下的人群,其免疫和抗体反应的发展及持续时间仍部分未知。这可能在再次感染的易感性中起作用。迄今为止,文献中仅报道了3例慢性血液透析患者再次感染新冠病毒(感染毒株早于奥密克戎变异株)的病例。在所有这些病例中,首次感染是在无症状的情况下通过筛查发现的,这可能表明免疫反应较差,而且没有关于所产生抗体滴度的数据。我们报告了一例2020年新冠病毒复发的病例——首次感染可能来自武汉毒株;7个月后再次感染可能来自英国变异株(阿尔法)——该病例为一名有临床症状和肺部超声异常的血液透析患者。两次发作期间的拭子检测均为阴性(因此排除了任何持续阳性的情况),血清学检测证明首次感染后缺乏抗体保护。考虑到新冠疫苗接种运动以及奥密克戎变异株的出现(奥密克戎变异株似乎能逃避疫苗和先前变异株诱导的免疫力),血液透析患者接触新冠病毒后潜在免疫保护缺乏或迅速丧失的作用需要进一步明确。为此,几个欧洲国家正在进行前瞻性多中心研究。该病例还凸显了即使在患者战胜感染和/或接种疫苗后,仍需在透析室用鼻咽拭子进行仔细筛查的必要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验